Life Science Leader Magazine Supplements

CRO Supplement 2015

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link:

Contents of this Issue


Page 33 of 51

THE CRO LEADERSHIP AWARDS 2015 LIFESCIENCELEADER.COM 34 KEY BUSINESS DECISIONS insights way towards alleviating the unhappiness caused by a change in project manager. WHAT TO DO WHEN THINGS GO WRONG No matter how well you vet your CRO, sometimes things will still not go as planned. That will happen with large CROs as well as small. Of course, how you approach the situation will determine your success at getting any situation resolved. If a study is not going according to plan, Strause recommends going to the business development person or higher. "Rarely do I believe these situations to be the fault of the project manager," she says. "At the same time, the person who will benefit the most from the client being happy is that BD person. Unfortunately, what will normally hap- pen is the project manager will simply be moved to another study. That is just the way things work in this world." There was only one time when Strause came close to removing a large CRO in mid-study. This was early on in the project, but she believes if you're going to make a move, it's better to do it sooner rather than later. She recommends doing it only if you truly feel you have nowhere left to turn. Still, knowing when to pull the plug is a difficult challenge. "That's the most difficult question to answer," she says. "To start, I think people have to be able to admit they made a mistake. That is difficult in and of itself. It was the hardest thing I ever had to do and I dreaded having to make that decision. I am all about metrics. If I see we are behind on the timeline and things are not being done correctly, I will go to the highest level executives I can reach. I would even go so far as to request bi-weekly calls with the clinical project manager and their line manager and that person's line manager. I feel you need to go up at least three levels to get to the directors and VPs of clinical operations. They will do everything in their power to make you happy, but if things are still not going as they should, you need to cut them loose. Sometimes companies are just not a match for each other." L WHY GO LARGE? If going with a large CRO has both benefits and drawbacks, how do you decide if a large CRO is the right fit for your company? Strause notes that discussions usually balance experience with culture. "Experience and technology are gener- ally the drivers I see at work," she says. "Technology is always important, and you want to make sure the CRO you select will have the proper technologies in house. I also see companies trying to rely too much on past experience. I don't necessarily agree that is the best approach, and I think companies can sometimes rely too much on the belief that if a company has done it before, they can do it again. In the drug development industry an investigational site may be a top enroller in one study and enroll poorly in another even if they are in the same therapeutic area. The same is often true of a CRO. There are too many variables that can change the outcome." Other parameters that influence deci- sions include financial stability and reputation of a CRO. A virtual company is very aware of financial instability and requires a fiscally strong CRO as a part- ner. Strause was forced to manage the impact on a pivotal oncology study when one of the CROs filed bankruptcy. It was very challenging and difficult. The CRO's reputation may also influence the com- pany's decision as having a well-known CRO may influence future partnerships or sale of the company. "I don't play in the funding space so I don't know if that is true or not, but my belief has always been that the data is good or it is bad. Neither the CRO nor the sponsor can make a product work. Only the data can tell us," she states. RESOURCE ALLOCATION OR BAIT-AND-SWITCH? One of the most important consider- ations for a small company working with a large CRO is knowing who will perform the work on your study. Oftentimes a sponsor will be told that one team or individual will do the work, only to have that change as soon as the study is under- way. While some sponsors will refer to that situation as bait-and-switch, on this topic Strause comes to the defense of the CROs. "I don't think it is bait-and-switch," she says, "and I do not think it is inten- tional. When a big CRO first comes in they will naturally bring their A-team. I have certainly been in situations where we get three months into a contract and suddenly I am dealing with a new project manager, but it's not bait-and-switch. I believe this situation has more to do with resource leveling and allocation. A large CRO deals with numerous clients, large and small, and each wants the best of the best. Everyone wants the A-team working on their project, but even in a large company, that is simply not always possible." Strause is currently working with a midsize CRO that she believes is taking a unique approach and making significant effort to meet the needs of the client. The business development person who made the sale continues to have a weekly call with the director of clinical opera- tions. With many of the larger CROs she has worked with, unless she has a com- plaint, she will never again hear from the business development contact. That type of personal attention can go a long By E. Miseta SMALL PHARMA AND LARGE CROs: CONSIDERATIONS FOR PARTNERING In the drug development industry an investigational site may be a top enroller in one study and enroll poorly in another even if they are in the same therapeutic area. L I N D A S T R A U S E , P H . D . Principal and Founder of Strategic Clinical Consultants

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine Supplements - CRO Supplement 2015